Base-Case Costs and Ranges for Variables in the Model*
Variable | Base-Case Cost, $ | Range in Sensitivity Analyses, $ |
γ Distributions for Monte Carlo Simulations
|
References | |
---|---|---|---|---|---|
α | λ | ||||
Cost of administering clinical criteria† | 50 | 40–60 | 11.11 | 0.22 | 90 |
| |||||
Cost of tumor testing | |||||
BRAF testing | 110 | 88–132 | 13.44 | 0.12 | 50 |
| |||||
IHC | 280 | 224–336 | 31.36 | 0.112 | 50 |
| |||||
MSI | 490 | 392–588 | 15.37 | 0.031 | 50 |
Cost of genetic testing and genetic counseling | |||||
| |||||
Germline test for 1 gene | 880 | 600–1200 | 19.36 | 0.022 | 50 |
| |||||
Single-site mutation testing | 460 | 200–475 | 9.40 | 0.020 | 50 |
| |||||
Approaching relative to offer genetic testing | 110 | 88–132 | 13.44 | 0.122 | 50 |
| |||||
Initial genetic counseling visit | 185 | 148–222 | 38.03 | 0.206 | 50 |
| |||||
Follow-up genetic counseling visit | 105 | 84–126 | 12.25 | 0.117 | 50 |
| |||||
Cost of screening and complications | |||||
Colonoscopy | 645 | 516–774 | 41.60 | 0.06 | 91 |
Colonoscopy complications | |||||
| |||||
Bleeding | 6218 | 4974–7462 | 17.18 | 0.003 | 90, 91 |
| |||||
Perforation | 10 304 | 8243–12 365 | 26.54 | 0.003 | 90, 91 |
| |||||
Polypectomy and pathology | 235 | 188–282 | 22.09 | 0.094 | 91 |
| |||||
Endometrial biopsy | 224 | 179–269 | 13.94 | 0.062 | 91 |
| |||||
Transvaginal ultrasonography | 110 | 88–132 | 13.44 | 0.012 | 91 |
| |||||
Cost of risk-reducing surgeries | |||||
TAH-BSO | 16 348 | 13 078–19 618 | 42.76 | 0.003 | 92 |
| |||||
Subtotal colectomy | 14 059 | 11 247–16 871 | 31.62 | 0.002 | 90, 91 |
| |||||
Cost of colorectal cancer care in patients who do not have the Lynch syndrome | |||||
Without screening | |||||
Initial | 43 471 | 34 777–52 165 | 18.90 | 0.0004 | 93 |
| |||||
Year 1 | 3496 | 2797–4195 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 2 | 3184 | 2547–3821 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 3 | 3002 | 2402–3602 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 4 | 2904 | 2323–3485 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 5 | 2845 | 2276–3414 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
In year of death | 52 440 | 41 952–62 928 | 27.50 | 0.0005 | 93 |
With screening | |||||
| |||||
Initial | 38 711 | 30 969–46 453 | 14.99 | 0.0004 | 93 |
| |||||
Year 1 | 2978 | 2382–3574 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 2 | 2801 | 2241–3361 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 3 | 2701 | 2161–3241 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 4 | 2647 | 2118–3176 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 5 | 2615 | 2092–3138 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
In year of death | 50 930 | 40 744–61 116 | 25.94 | 0.0005 | 93 |
Cost of colorectal cancer care in patients with the Lynch syndrome | |||||
Without screening | |||||
Initial | 38 568 | 30 854–46 282 | 14.87 | 0.0004 | 93 |
| |||||
Year 1 | 3060 | 2448–3672 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 2 | 2839 | 2271–3407 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 3 | 2715 | 2172–3258 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 4 | 2649 | 2119–3179 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 5 | 2610 | 2088–3132 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
In year of death | 51 978 | 41 582–62 374 | 27.02 | 0.0005 | 93 |
With screening | |||||
| |||||
Initial | 33 711 | 26 969–40 453 | 11.36 | 0.0003 | 93 |
| |||||
Year 1 | 2457 | 1966–2948 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 2 | 2447 | 1958–2936 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 3 | 2439 | 1951–2927 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 4 | 2433 | 1946–2920 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
Year 5 | 2428 | 1942–2914 | Not varied in sensitivity analyses | Not varied in sensitivity analyses | 93 |
| |||||
In year of death | 49 210 | 39 368–59 052 | 24.22 | 0.0005 | 93 |
| |||||
Cost of cancer care | |||||
Endometrial cancer | 31 027 | 24 822–37 232 | 15.04 | 0.0005 | 92 |
| |||||
Ovarian cancer | 32 379 | 25 903–38 855 | 10.48 | 0.0003 | 94 |
IHC = immunohistochemistry; MSI = microsatellite instability; TAH-BSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy.
All costs are in 2010 U.S. dollars.
Amsterdam II criteria, revised Bethesda Guidelines, or prediction models (MMRpredict, MMRpro, and PREMM[1,2,6]).